Dr. Libuse Tauchmanova is an experienced clinical development leader with expertise in radiopharmaceuticals, oncology, rare diseases, and endocrinology. She has held senior clinical development roles at Molecular Partners, Telix Pharmaceuticals, Debiopharm, Novartis, and Advanced Accelerator Applications, where she served as Medical Lead for the pivotal Phase 3 VISION trial of 177Lu-PSMA-617.
Throughout her career, Libuse has led global clinical strategy and development across Phase 1 through Phase 3 programs and contributed to regulatory submissions across major international markets. She brings a science-driven, collaborative approach to translating innovative therapies into meaningful treatments for patients.